This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Momenta Pharmaceuticals' CEO Presents At Goldman Sachs 33rd Annual Global Healthcare Conference (Transcript)

Momenta Pharmaceuticals, Inc. (MNTA)

Goldman Sachs 33rd Annual Global Healthcare Conference

June 7, 2012 12:20 p.m. ET

Executives



Craig Wheeler - CEO

Analysts



Sapna Srivastava - Goldman Sachs



Presentation



Sapna Srivastava - Goldman Sachs



Thank you. Good morning and thanks for joining us. I am Sapna Srivastava, biotech analyst at Goldman Sachs. And it’s my pleasure to host Craig Wheeler, CEO of Momenta. And thank you so much Craig for coming, really appreciate to know with the trip (indiscernible) with the morning here.

Before we go into the discussion, I just want to read this out to the audience. We’re required to make certain disclosures and public appearances about Goldman Sachs’ relationships with companies that we discuss. The disclosures relate to investment banking relationships’ compensation received or 1% or more ownership. I am prepared to read disclosures if anyone would like me to, however, these disclosures are available in our most recent reports available to U.S. clients on our firm’s portals. Views of non-Goldman Sachs personnel may not represent the company views.

And with that, I will kick it off, and just a reminder to the audience we would like this to be interactive. So please ask as many questions as you have. Craig, when we sat down here last year, it’s amazing to me how much has happened at Momenta since then, from the Lovenox side of it to the Baxter side of it. I would just love to get your views over like, this really I think a period of massive activity and evolution of the company, where do you see your most – your largest key opportunities now and where you are most focused for taking the company towards?

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs